Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-2441
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer ; volume:23 ; number:1 ; day:14 ; month:8 ; year:2022 ; pages:1-11 ; date:12.2022
The Egyptian journal of medical human genetics ; 23, Heft 1 (14.8.2022), 1-11, 12.2022
- Creator
-
Boucenna, Amira
Boudaoud, Khadidja
Hireche, Ahmed
Rezgoune, Mohamed Larbi
Abadi, Noureddine
Filali, Taha
Satta, Dalila
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43042-022-00332-7
- URN
-
urn:nbn:de:101:1-2022110118280877937841
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boucenna, Amira
- Boudaoud, Khadidja
- Hireche, Ahmed
- Rezgoune, Mohamed Larbi
- Abadi, Noureddine
- Filali, Taha
- Satta, Dalila
- SpringerLink (Online service)
Other Objects (12)
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Frequencies of CYP2D6 genetic polymorphisms in Arab populations
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic polymorphisms analysis of CYP2D6 in the Uygur population
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
Impact of APOE gene polymorphisms on the lipid profile in an Algerian population
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Frequencies of CYP2D6 genetic polymorphisms in Arab populations
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic polymorphisms analysis of CYP2D6 in the Uygur population
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
Impact of APOE gene polymorphisms on the lipid profile in an Algerian population
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Frequencies of CYP2D6 genetic polymorphisms in Arab populations
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Genetic polymorphisms analysis of CYP2D6 in the Uygur population
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients